ReviewPharmacology & therapeutics2008
AT2 receptors: functional relevance in cardiovascular disease.
Review in Pharmacology & therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 237 citations in OpenAlex.
- Renoprotective effects of compound 21 and empagliflozin in L-Name-induced hypertensive rats.BMC urology · 2025Article
- The Renin-Angiotensin-Aldosterone System (RAAS): Beyond Cardiovascular Regulation.Veterinary sciences · 2025Review
- The novel AT2 receptor ligand, β-Pro7 Ang III, induces equivalent anti-fibrotic effects to Compound 21 but broader anti-fibrotic effects than pirfenidone in mice with bleomycin-induced pulmonary fibrosis.Clinical science (London, England : 1979) · 2025Article
- Mechanisms of angiotensin II to induce depression in diabetes.Diabetology international · 2025Review
- Angiotensin II and Cardiovascular Disease: Balancing Pathogenic and Protective Pathways.Current issues in molecular biology · 2025Review
- A perspective on small molecules targeting the renin-angiotensin-aldosterone system and their utility in cardiovascular diseases: exploring the structural insights for rational drug discovery and development.RSC medicinal chemistry · 2025Review
- Developmental Impacts of Epigenetics and Metabolism in COVID-19.Journal of developmental biology · 2024Review
- Stimulation of angiotensin II type 2 receptor attenuates organ injury in rats with polymicrobial sepsis.Journal of the Chinese Medical Association : JCMA · 2023Article
- Evidence of Renin-Angiotensin System Receptors in Deep Fascia: A Role in Extracellular Matrix Remodeling and Fibrogenesis?Biomedicines · 2022Article
- The Angiotensin ATPharmacological reviews · 2022Review
- Role of angiotensin II in aging.Frontiers in aging neuroscience · 2022Review
- Pharmaceutical Potential of Casein-Derived Tripeptide Met-Lys-Pro: Improvement in Cognitive Impairments and Suppression of Inflammation in APP/PS1 Mice.Journal of Alzheimer's disease : JAD · 2022Article
- Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS.JCI insight · 2021Article
- Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3‑induced pyroptosis via the TAK1/JNK signaling pathway.Molecular medicine reports · 2021Article
- The Tissue Renin-Angiotensin System and Its Role in the Pathogenesis of Major Human Diseases: Quo Vadis?Cells · 2021Review
- Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?Archives of medical science : AMS · 2021Article
- Extracellular and Intracellular Angiotensin II Regulate the Automaticity of Developing CardiomyocytesFrontiers in molecular biosciences · 2021Article
- Review
- Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2.European journal of pharmacology · 2020Review
- Microglia mediated neuroinflammation - signaling regulation and therapeutic considerations with special reference to some natural compounds.Histology and histopathology · 2020Review
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The renin angiotensin system (RAS) is intricately involved in normal cardiovascular homeostasis. Excessive stimulation by the octapeptide angiotensin II contributes to a range of cardiovascular pathologies and diseases via angiotensin type 1 receptor (AT1R) activation. On the other hand, tElsevier Inc.he angiotensin type 2 receptor (AT2R) is thought to counter-regulate AT1R function. In this review, we describe the enhanced expression and function of AT2R in various cardiovascular disease settings. In addition, we illustrate that the RAS consists of a family of angiotensin peptides that exert cardiovascular effects that are often distinct from those of Ang II. During cardiovascular disease, there is likely to be an increased functional importance of AT2R, stimulated by Ang II, or even shorter angiotensin peptide fragments, to limit AT1R-mediated overactivity and cardiovascular pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.